Spyre Therapeutics, Inc. SYRE Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s retained earnings?
- Spyre Therapeutics, Inc. (SYRE) reported retained earnings of -$1.2B in Q1 2026.
- How has Spyre Therapeutics, Inc.'s retained earnings changed year-over-year?
- Spyre Therapeutics, Inc.'s retained earnings decreased by 17.6% year-over-year, from -$1.02B to -$1.2B.
- What is the long-term trend for Spyre Therapeutics, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s retained earnings has grown at a 32.5% compound annual growth rate (CAGR), from -$276.01M to -$1.13B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.